ABL Diagnostics H1 FY26 net income rises to €1.28 million; revenue climbs 90% to €5.42 million

Reuters2026/09/08 16:28

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ABL Diagnostics posted H1 2026 revenue of EUR 5.42 million, up 90% from H1 2025; net income rose 343.4% to EUR 1.28 million.
EBITDA more than doubled to EUR 1.32 million; EBITDA margin widened 14 percentage points to 24.3%.
Operating income turned to a profit of EUR 1.12 million from an operating loss; available cash fell 35.2% to EUR 853,000.
Managing Director Chalom Sayada cited ramp-up of historical activities and new growth drivers, including UltraGene and software, supporting profitability.
Maintained 2026 revenue target of EUR 12.27 million; plans to update guidance to reflect the Texcell France asset acquisition completed July 21.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260908089476) on September 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ABL Diagnostics H1 FY26 net income rises to €1.28 million; revenue climbs 90% to €5.42 million

You may also like

Crypto prices